Briacell Therapeutics Corp
BCTX
查看详细走势图
8.950USD
-0.060-0.67%
收盘 12/19, 16:00（美东）报价延迟15分钟
16.86M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.67%
5天
-6.18%
1月
+27.49%
6月
-70.75%
今年开始到现在
-89.44%
1年
-89.36%
查看详细走势图
TradingKey Briacell Therapeutics Corp股票评分
单位: USD 更新时间: 2025-12-19操作建议
Briacell Therapeutics Corp当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名166/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价40.00。中期看，股价处于下降通道。近一个月，市场表现较强，基本面评分较高，但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Briacell Therapeutics Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
40.000
目标均价
+199.85%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Briacell Therapeutics Corp亮点
亮点风险
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值高估
公司最新PE估值-0.26，处于3年历史高位
活跃度降低
近期活跃度降低，过去20天平均换手率-0.82
Briacell Therapeutics Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Briacell Therapeutics Corp简介
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
公司代码BCTX
公司Briacell Therapeutics Corp
CEOWilliams (William V)
网址https://briacell.com/
常见问题
Briacell Therapeutics Corp(BCTX)的当前股价是多少？
Briacell Therapeutics Corp(BCTX)的当前股价是 8.950。
Briacell Therapeutics Corp的股票代码是什么？
Briacell Therapeutics Corp的股票代码是BCTX。
Briacell Therapeutics Corp股票的52周最高点是多少？
Briacell Therapeutics Corp股票的52周最高点是139.500。
Briacell Therapeutics Corp股票的52周最低点是多少？
Briacell Therapeutics Corp股票的52周最低点是8.400。
Briacell Therapeutics Corp的市值是多少？
Briacell Therapeutics Corp的市值是16.86M。
Briacell Therapeutics Corp的净利润是多少？
Briacell Therapeutics Corp的净利润为-26.31M。
现在Briacell Therapeutics Corp(BCTX)的股票是买入、持有还是卖出？
根据分析师评级，Briacell Therapeutics Corp(BCTX)的总体评级为买入，目标价格为40.000。
Briacell Therapeutics Corp(BCTX)股票的每股收益（EPS TTM）是多少
Briacell Therapeutics Corp(BCTX)股票的每股收益（EPS TTM）是-33.869。
相关品种
